Bo Q, et al. – The primary goal of this study was to examine remission following the treatment of schizophrenia patients with risperidone. Results of this study suggested that a shorter illness duration, risperidone treatment length, and a lower total Positive and Negative Syndrome Scale (PANNS) score were clinically valuable predictors of remission. Achieving remission might postpone relapse.